Dupilumab Demonstrates a Significantly Higher Likelihood of Achieving Improvements in Atopic Dermatitis Signs and Itch vs Nemolizumab at Week 16 in Combination With Topical Corticosteroids: Results From a Bucher Placebo-Adjusted Indirect Comparison. J of Skin [Internet]. 2026 Mar. 10 [cited 2026 May 2];10(2):s738. Available from: https://skin.dermsquared.com/skin/article/view/4061